Challenges in Cancer Treatment


Prevalence: Cancer is a leading cause of death globally, with approximately 9.6 million deaths per year.


Side Effects: Common treatments like chemotherapy and radiotherapy can have significant adverse effects, including but not limited to: Hair loss (alopecia); Anemia and; Skin damage (post-radiative dermatitis)


Complexities: Advanced stages of cancer often lead to treatment resistance. The overall health of the patient can deteriorate, leading to treatment failure



IMDENDRIM's Edge in Nanomedicine for Cancer Treatment

Unique Value Proposition 

  • IMDENDRIM utilizes advanced nanotechnology to target solid tumors with unprecedented precision, minimizing damage to surrounding healthy tissues and reducing side effects typically associated with conventional cancer treatments.

Proprietary Technology 
and Patents

  • Awarded with a world patent 
    (World Patent: PCT/182014/058238) which include the unique mechanisms of action, delivery systems and manufacturing processes that contribute to IMDENDRIM's effectiveness and safety.

Strategic Positioning and 
Market Opportunity

  • With the cancer therapies market expected to soar beyond $400 billion by 2033, whilst IMDENDRIM is perfectly placed to meet the increasing demand for cancer treatments that are both effective and less invasive. This market trend presents a prime opportunity for IMDENDRIM to shine. 

Nano Gun Technology

Leadership Profile

Founded in 2017 by the Inventors of the Imdendrim Patent
A Young and Innovative Biotech Company

Our Team

Extensive Expertise in Pharmaceutical Research




Pharmacist PhD in Toxicology




PhD in ChemistryMD in PharmacologyDES in Oncology-Radiotherapy

Multidisciplinary Partnership Phases


Chemical/Pharmaceutical Production
(GMP Kit)

  • Production of nanomedicine kits (Colcom/ERAS lab/ NGT)
  • Natives DGL, Customization, Scale-up, GMP

Radio-pharmaceutical Production 

  • Labelling and quality control (Radio pharmacy platform
  • Radio Labelling, automatic process, TLC control, GMP Production/lot

Pre-clinical Expertise

  • Invitro and In vivo tests (CELVAX labs, AFPREMED)
  • Molecular biology, Human tumor/tissue samples, Pharmacokinetic & pharmacodynamic models

Market Analysis

The global market for cancer therapies was valued at approximately USD 158 billion in 2020 and is projected to reach about USD 268 billion by 2026, marking a significant growth trend with a Compound Annual Growth Rate (CAGR) of 9.15% over the forecast period. This growth is reflective of the increasing demand for personalized medicine, rising government initiatives for cancer awareness, and the growing prevalence of cancer worldwide.

Among the various segments within the cancer therapy market, the treatment segment, including traditional chemotherapy, targeted therapy, immunotherapy, and hormonal therapy, dominates due to its effectiveness and advancements in reducing side effects compared to traditional methods.

$220 BN

2023 Market Valuation

Estimated to reach $490 BN by 2032


CAGR in 2020

IMDENDRIM in Lung Cancer Treatment

Imdendrim has been demonstrated as safe and welltolerated in clinical trials.

All 5 patients showed positive responses at 12 weeks, withtwo achieving complete remission.

The award from CONQUER CANCER® at the BreakthroughSummit recognizes the groundbreaking impact of thisresearch.

Ongoing Clinical Trial:
MDENDRIM's Impact on Lung Cance
  • Currently, 12 patients are actively participating in the trial.
  • Significant findings have been published in various medical journals,demonstrating the potential of IMDENDRIM:
    • Belhadj-Tahar, Hafid, et al. "In situ anti-cancer agent derived from[^188Re] rhenium nitro-imidazole ligand loaded poly-l-lysinedendrimer administered by direct CT guided stereotactic intrahepaticinjection." Journal of Clinical Oncology, vol. 36, no 15_suppl.
    • H. Belhadj-Tahar, N. Sadeg, and G. Yang. "Intra-Tumoral HepaticAdministration Under CT Stereotactic and Ultrasound Guidance of inSitu Anti-Cancer Agent Derived from [^188Re] Rhenium NitroImidazole Ligand Loaded 5th Generation Poly-L-Lysine Dendrimer."International Journal of Radiation Oncology, Biology, Physics 105.1(2019): E642.

Future Directions

Clinical Trials for Aggressive

& Lethal Cancers  (Pancreas, Brain, Lung)

Timeframe: 6-12 months
Action Items: List of trial phases (Phase I/II, etc.)

Marketing Authorization

(European Marketing)

Timeframe: 24 months
Action Items: Regulatory submissions, 
interactions with EMA, etc.

Business Expansion


Timeframe: 60 months
Action Items: Strategic partnerships, 
global market analysis, etc.

Get in touch

Contact us for futher information or if you want to donate to our research, 
reach out to us at